Lin 2017.

Methods	Study design: Randomised clinical trial Study duration: February 2016 to January 2017 Duration of follow‐up: 3 months Setting: Hospital
Participants	Inclusion criteria: No serious diseases in other organs; tumour numbers < 3; no tumour thrombus in inferior vena cava or portal vein; no extrahepatic metastasis Age (mean ± SD, range): TACE + RFA: 50.1 ± 2.5 years, 34‐68 years; TACE: 49.2 ± 2.3 years, 33‐67 years Male (n/total): TACE + RFA: 22/30; TACE alone: 21/30 Child‐Pugh Class (patients): Class A: TACE + RFA: 22; TACE: 21 Class B: TACE + RFA: 5; TACE: 6 Class C: TACE + RFA: 3; TACE: 3
Interventions	TACE + RFA group (n = 30): TACE: Chemotherapeutic drugs: theprubicin 50 mg, mitomycin 10 mg, and cisplatin 50 mg RFA: The interval between TACE and RFA was 2 weeks. Output power of 200 W. Total treatment time of 10‐30 minutes TACE group (n = 30): Chemotherapeutic drugs: theprubicin 50 mg, mitomycin 10 mg, and cisplatin 50 mg
Outcomes	Tumour necrosis: measured by DSA or CT Tumour recurrence
Notes	Funding source: None Conducted in China There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.